biostudies-literatureZabaleta ALa Caixa FoundationCancer Research UK (A26819), FCAECC and AIRC under the Accelerator Award Programme (EDITOR)Instituto de Salud Carlos IIIRiney Family Multiple Myeloma Research ProgramInstituto de Salud Carlos III/Subdirección General de Investigación Sanitaria, (cofunded by the EU)Black Swan Research Initiative of the International Myeloma FoundationFundación Científica Asociación Española Contra el CáncerCIBER-Consorcio Centro de Investigación Biomédica en Red - Área de Oncología - Instituto de Salud Carlos III, Ministerio de Ciencia e InnovaciónCRIS Cancer Foundation93-102https://www.ebi.ac.uk/biostudies/studies/S-EPMC11625977biostudies-literatureUnknown100(1)The impact of measurable residual disease (MRD) in relapse/refractory multiple myeloma (RRMM) patients treated with T-cell redirecting immunotherapy is uncertain. We analyzed MRD dynamics using next-generation flow in 201 patients treated in clinical trials with chimeric antigen receptor (CAR) T cells and T-cell engagers (TCE). Achieving MRD negativity at 10^-6 was associated with 89% reduction in the risk of progression and/or death. Survival outcomes were improved in patients with sustained versus transient MRD negativity and were dismal in those who remained MRD positive. The intent-to-treat MRD negative rates were higher in patients treated with CAR T cells versus TCE. However, among patients achieving MRD negativity, there were no differences in survival outcomes when stratiAmerican journal of hematologyClinical significance of complete remission and measurable residual disease in relapsed/refractory multiple myeloma patients treated with T-cell redirecting immunotherapy.PMC11625977PR_EX_2020‐02PI19/01451CB16/12/00233ICI19/00025PI21/01816CP042702/LCF/PR/GN18/50310007CB16/12/00369CB16/12/00489PI22/00647PR_EX_2020-02Moreno CMateos MVPuertas BZabaleta ABlade JLopez-Corral LUrbano ACedena MTPuig NTamariz-Amador LELopez-Munoz NRey-Bua BMartinez-Lopez JJuan Mde Larrea CFRodriguez-Otero PPerez JJProsper FMiras FPaiva BGonzalez-Calle VSan Miguel JFGonzalez-Navarro EALahuerta JJSanchez-Pina JMOliver-Caldes AfalseClinical significance of complete remission and measurable residual disease in relapsed/refractory multiple myeloma patients treated with T-cell redirecting immunotherapy.The impact of measurable residual disease (MRD) in relapse/refractory multiple myeloma (RRMM) patients treated with T-cell redirecting immunotherapy is uncertain. We analyzed MRD dynamics using next-generation flow in 201 patients treated in clinical trials with chimeric antigen receptor (CAR) T cells and T-cell engagers (TCE). Achieving MRD negativity at 10^-6 was associated with 89% reduction in the risk of progression and/or death. Survival outcomes were improved in patients with sustained versus transient MRD negativity and were dismal in those who remained MRD positive. The intent-to-treat MRD negative rates were higher in patients treated with CAR T cells versus TCE. However, among patients achieving MRD negativity, there were no differences in survival outcomes when strati2025-01-01T00:00:00Z2025 Jan2025-04-18T13:09:40.281Z2025-04-06T22:42:27.548ZS-EPMC116259773954882710.1002/ajh.27526